Physician profile
Richard E Rupp
NPI 1700893625
$20,135.39
in general payments reported to CMS, 2019-2025
5 companies · $3,890 in 2025
The $3,890 reported for 2025 was more than what 98% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,692 · 2020: $216 · 2021: $1,090 · 2022: $2,776 · 2023: $4,594 · 2024: $5,876 · 2025: $3,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Travel and Lodging: $1,951 · Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,406.36 |
| Travel and Lodging | $1,950.72 |
| Food and Beverage | $1,003.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12,147.15 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $4,547.54 | 2020-2025 | |
| Modernatx, INC. | $1,728.38 | 2023 | |
| Pfizer INC. | $1,712.32 | 2019-2021 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.